1. Home
  2. CRSP vs BMA Comparison

CRSP vs BMA Comparison

Compare CRSP & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • BMA
  • Stock Information
  • Founded
  • CRSP 2013
  • BMA 1966
  • Country
  • CRSP Switzerland
  • BMA Argentina
  • Employees
  • CRSP N/A
  • BMA N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • BMA Commercial Banks
  • Sector
  • CRSP Health Care
  • BMA Finance
  • Exchange
  • CRSP Nasdaq
  • BMA Nasdaq
  • Market Cap
  • CRSP 4.0B
  • BMA 4.7B
  • IPO Year
  • CRSP 2016
  • BMA 2006
  • Fundamental
  • Price
  • CRSP $47.25
  • BMA $80.22
  • Analyst Decision
  • CRSP Buy
  • BMA Hold
  • Analyst Count
  • CRSP 19
  • BMA 2
  • Target Price
  • CRSP $73.69
  • BMA $70.00
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • BMA 258.8K
  • Earning Date
  • CRSP 11-05-2024
  • BMA 11-26-2024
  • Dividend Yield
  • CRSP N/A
  • BMA 26.96%
  • EPS Growth
  • CRSP N/A
  • BMA 47.87
  • EPS
  • CRSP N/A
  • BMA 0.81
  • Revenue
  • CRSP $202,829,000.00
  • BMA $3,807,436,394.00
  • Revenue This Year
  • CRSP N/A
  • BMA N/A
  • Revenue Next Year
  • CRSP $526.27
  • BMA N/A
  • P/E Ratio
  • CRSP N/A
  • BMA $11.09
  • Revenue Growth
  • CRSP 19.31
  • BMA 17.14
  • 52 Week Low
  • CRSP $43.42
  • BMA $19.02
  • 52 Week High
  • CRSP $91.10
  • BMA $83.69
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 44.94
  • BMA 60.87
  • Support Level
  • CRSP $50.60
  • BMA $76.60
  • Resistance Level
  • CRSP $59.07
  • BMA $81.00
  • Average True Range (ATR)
  • CRSP 2.84
  • BMA 3.89
  • MACD
  • CRSP -0.35
  • BMA -0.21
  • Stochastic Oscillator
  • CRSP 7.48
  • BMA 67.32

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.

Share on Social Networks: